RADNOR, Pa., April 24, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securitiesduring the Class Period may, no later than June 11, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail firstname.lastname@example.org; orclick https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. The Class Period commences on November 8, 2019 when FibroGen issued a press release announcing "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results". In the press release, and throughout the Class Period, FibroGen touted roxadustat as a safe treatment for anemia of chronic kidney disease ("CKD").
However, the truth was revealed on April 6, 2021 when, after the market closed, FibroGen issued a press release that revealed that FibroGen's previously disclosed safety data included undisclosed post-hoc changes to the stratification factors and did not include analyses based on the pre-specified stratification factors. As a result of these changes, the complaint alleges that FibroGen was forced to concede that roxadustat, contrary to prior representations, did not reduce the risk of cardiovascular events or hospitalization as compared to a currently approved anemia injection used as a control based on pre-specified stratification factors. Following this news, FibroGen's stock price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021. The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) FibroGen's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia and certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (2) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (3) based on these analyses FibroGen could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (4) as a result, FibroGen faced significant uncertainty that its New Drug Application for roxadustat as a treatment for anemia of CKD would be approved by the U.S. Food and Drug Administration; and (5) as a result of the foregoing, the defendants' statements about FibroGen's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.FibroGen investors may, no later than June 11, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.CONTACT:
Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)email@example.com View original content to download multimedia:https://www.prnewswire.com/news-releases/deadline-reminder-kessler-topaz-meltzer--check-llp-reminds-investors-of-securities-fraud-class-action-lawsuit-filed-against-fibrogen-inc-fgen-301276255.htmlSOURCE Kessler Topaz Meltzer & Check, LLP
SINGAPORE, April 27, 2021 /PRNewswire/ -- Diginex Limited (Nasdaq: EQOS), a digital assets financial services company, announced today that it has entered into strategic partnerships with algorithmic trading firm Kronos Research, and institutional liquidity provider Parallel.As part of the partnerships, both Kronos and Parallel will serve as liquidity providers on EQUOS, the cryptocurrency exchange platform of Diginex, and become shareholders in Diginex. Fees paid by both partners will also secure them EQO, the unique exchange token of EQUOS.The addition of Kronos and Parallel as liquidity providers, follows an announcement made earlier this year, that Diginex had entered into an agreement with GSR to become a liquidity provider for EQUOS, and a shareholder of Diginex. Richard Byworth, CEO at Diginex, said: "From the outset, we designed EQUOS to be transparent and fair. We do not market make on our own exchange and as such, it is very important to have long term partners to provide liquidity. Today's announcement is a part of a continuing focus around increasing the depth of markets and broad liquidity that provides EQUOS users with best execution pricing."Earlier this month, EQUOS announced record total volumes of over US$1 billion in April month to date, with average daily volumes during the period increasing over three times compared to average daily volumes in the prior month. Volumes have been driven by the launch of EQO and a significant increase in participation by a number of institutional clients. Parallel has played an important role in fuelling EQUOS' recent volume growth.
"Parallel's technology has been an integral part of fuelling EQUOS growth, helping the exchange exceed $1 billion in volume in the last 30 days," added Byworth. Timothy Tam, CEO of Parallel - one of the fastest growing liquidity providers in crypto, said: "We only partner with a few select companies in the crypto ecosystem and Diginex's strong corporate governance as a Nasdaq listed entity, institutional-grade custody and state of the art exchange made it a natural choice. We are proud to be a strategic partner of Diginex and look forward to being a significant contributor to EQUOS' exponential growth." Parallel and Kronos will provide liquidity on all markets on EQUOS, including recently launched BTC and ETH Perpetual Futures contracts, as well as supporting future listings. Jack Tan, co-CEO at Kronos Research, added: "We are delighted to partner with EQUOS and become a shareholder in Diginex. Both our missions align seamlessly. Our robust trading and research infrastructure which includes the Wootrade network can support the EQUOS focus on transparency and innovation. This means together we will be able to provide superior liquidity so investors can achieve their goals."About Diginex
Diginex is a digital assets financial services company focused on delivering a cryptocurrency and digital assets ecosystem offering innovative product and services that are compliant, fair and trusted. The group encompasses cryptocurrency exchange EQUOS.io as well as an over-the-counter trading platform. It also offers a front-to-back integrated trading platform, Diginex Access, a securitisation advisory service, Diginex Capital, market leading hot and cold custodian Digivault and funds business Bletchley Park.For more information visit: https://www.diginex.com/Follow Diginex on social media on Twitter @DiginexGlobal, on Facebook @DiginexGlobal, and on LinkedIn.About Kronos Research Kronos Research is one of the largest quantitative trading firms in the cryptocurrency industry by volume, generating over $5 billion per day across global exchanges. Kronos delivers superior trading performance and liquidity through our advanced trading infrastructure and deep quantitative research capabilities. In 2019, Kronos Research incubated Wootrade, a liquidity aggregation and trading platform that connects to over 15 institutions, as well as decentralized finance and retail trading platforms.About Parallel
Parallel is the fastest growing liquidity provider in crypto. Its proprietary liquidity provision technology allows users to buy and sell crypto at the market's true best price and powers 1% of global crypto trading volume. Parallel's technology currently trades US$2 billion a day and executes over 3 million individual trades a month, fully automated. To learn more about Parallel email firstname.lastname@example.orgThis press release is provided by Diginex Limited ("Diginex") for information purposes only, is a summary only of certain key facts and plans of Diginex and includes forward-looking statements that involve risks and uncertainties. Without limitation, the press release does not constitute an offer or solicitation in relation to any securities or other regulated products or services or to make use of any services provided by Diginex, and neither this press release nor anything contained in it will form the basis of any contract or commitment whatsoever. The contents of this press release have not been reviewed by any regulatory authority in any jurisdictions. Forward looking statements are statements that are not historical facts and are subject to risks and uncertainties, which could cause actual results or outcomes to differ materially from the forward-looking statements. Most of these factors are outside of Diginex's control and are difficult to predict. Factors that may cause such differences include, but are not limited to the ability to achieve the anticipated benefits of the strategic partnerships; the ability of Diginex to grow and manage growth profitably; Diginex's limited operating history and history of net losses; Diginex's ability to execute its business plan; the inability to maintain the listing of Diginex's shares on Nasdaq; Diginex's estimates of the size of the markets for its products; the rate and degree of market acceptance of Diginex's products; Diginex's ability to identify and integrate acquisitions; potential litigation involving Diginex or the validity or enforceability of Diginex's intellectual property; general economic and market conditions impacting demand for Diginex's products and services; and such other risks and uncertainties indicated in Diginex's Shell Company Report on Form 20-F, including those under "Risk Factors" therein, and in Diginex's other filings with the SEC, which are available on the SEC's website at www.sec.gov. In addition, any forward-looking statements contained in this press release are based on assumptions that Diginex believes to be reasonable as of this date. Diginex undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Other than those of Diginex, all names, trademarks and logos in this press release and used in the materials herein belong to their respective owners. Nothing contained on this press release should be construed as granting, by implication, estoppel, or otherwise, any right or license to use any third-party names, trademarks, or logos displayed on the press release without the written permission of such third parties. Copyright (c) Diginex 2021. View original content:https://www.prnewswire.com/news-releases/equos-announces-two-new-strategic-liquidity-providers-301277772.html
SOURCE Diginex Limited
(RTTNews) - European stocks are likely to open higher on Monday as investors await fresh cues from central bank meetings.
The Fed's next meeting ends on Wednesday, with Chair Jerome Powell likely to repeat ECB President Lagarde's message that talk of tapering is premature.
The Bank of Japan releases its latest rate decision on Tuesday and the central bank is widely seen standing pat following its policy framework tweaks last month.
Asian markets held near six-week highs and the dollar hit a two-month low at the start of a busy week of corporate earnings, with Tesla, Starbucks, Microsoft and Amazon set to report results.
Joe Biden makes his first address as president to a joint session of Congress Wednesday while the U.S. releases the first estimates for the March quarter GDP on Thursday.
Gold edged higher on dollar weakness while oil prices eased on concerns that a resurgence of coronavirus infections in India and Japan would cut fuel demand in Asia.
Turkey's lira edged lower and hovered near a record low due to worsening relations with the United States and worries about a dovish central bank governor.
Germany's ifo business confidence survey results for April are due later in the session. Economists expect the business climate index to rise to 97.8 from 96.6 in March.
U.S. stocks advanced on Friday as healthy economic data and earnings outweighed concerns about high valuations and surging coronavirus cases globally.
The Dow rose 0.7 percent, the tech-heavy Nasdaq Composite climbed 1.4 percent and the S&P 500 rallied 1.1 percent.
European stocks closed mostly lower on Friday despite coming off their day's lows on the back of a slew of earnings announcements and economic data.
The pan European Stoxx 600 edged down 0.1 percent. The German DAX dipped 0.3 percent and France's CAC 40 index slipped 0.2 percent while the U.K's FTSE 100 ended on a flat note.